Member Info for The_Paladin

Twice a week, I go through a process of dummy buying & selling on my broker’s site to ascertain the state of the share price. Currently, the buy/sell prices are 0.837p/0.800p, and my holding is valued mid-range at 0.817p. A grim position. When TEB disposed of his family’s assets, the share price was vastly reduced, and with it credibility in the company. The share price is around 15% of its end of 2023 level. It has not risen beyond around 1.9p since then.

The information released by RNS, and LinkedIn/X has amounted to nothing. There is never a statement of potential revenues; nor are there any broker assessments of note.

I believe in IB’s work, and potential, and will remain invested for that reason. However, it is high time that investors were offered something tangible to reinforce that belief.

TEB has utilised placements at very low share prices in recent years to keep IQ-AI afloat IMHO. It is high time that something of value emerged to justify the associated dilution of investors’ shareholdings.

GLALTIs.

Thank you Phil,

The narrative from a patient perspective is always worth reading. It highlights the importance of IB’s work.

“the importance of complementary approaches to fighting cancer, and the positive impact that it can have on patient outcomes”

IB’s precision imaging and diagnostics, and the GaM treatment are potentially part of the complementary pathways that could be made available to all patients with recurring glioblastoma.

The former enables more accurate diagnosis and greater precision in surgical techniques, whereas the latter shows significantly improved survival times from the patient cohort trialled to date. There is no cure available at present, but IB are making progress, and their work is benefiting patients.

Hopefully their progress will be recognised, and granted an accelerated pathway to further trialling.

I agree Tyke, although some of today’s activity seems to be down to day traders, as max pointed out earlier.

I added some on this news - @ 0.862p. I am now more confident of an eventual upward shift from our current level.

Of course, the “tinkerer” could well have another card up his sleeve to play? Let us hope not for the sake of IB’s outstanding work, which deserves full support from all involved.

It is high time for LTIs to receive some encouragement through a significant upward shift in the share price. All the positive messages that we are constantly receiving indicate that we are somewhat undervalued.

GLA.

Currently 100,00 shares can be bought @ 0.87p per share, and sold for 0.8202p per share.

Once again, excellent news from IB has resulted in an early selling trend? Short term traders? I find this most weird. Let us see what the rest of the day brings?

Thank you Tyke.

It is time that semantic realised that this forum mostly consists of LTIs, who are seeking an improvement in IB Plc's growth prospects. The fact that TEB's trading activity has seriously inhibited our short term progress cannot be swept under the carpet and forgotten. It seems obvious to me that semantic is closely allied with the company. Some of his statements have borne strong similarities to company RNSs.

Some reassurance from semantic, or TEB that our prospects won't be further inhibited by our CEO's apparent self-interest would be welcome. It is more usual for senior company personnel to buy shares as a statement of support than to sell c. 30% of the company, presumably for personal gain?

The imminent company name change and new website, if utilised properly will no doubt help our prospects. With full backing from all senior personnel, both in their roles, and with their full focus on the company, as opposed to their personal gain from it, would be helpful in accelerating our near term growth prospects.

GLA

I have been invested in this company for several years. During that time, our imaging technology has been promoted as “state of the art”, mostly by IB in their stream of X messages, and in MS’s newsletters. These have been steadily reinforced by RNSs, and through messages from other senior company personnel.

Why is it that, despite the quality of what the company has available, we are slow in gaining traction? Will the imminent rebranding, and new website have a positive effect? IMHO, there needs to be a significant increase in revenue from our diagnostic technologies, and/or a significant statement on the progress of the GaM trial, before we start to attract serious attention?

I am also of the view that the market activity in recent years is not indicative of the company’s achievements or its future potential? Like a number of micro -companies, investors/traders take a short term position in anticipation of quick returns. When this doesn’t happen, they move their investment capital elsewhere? This is my opinion, DYOR etc. How else does one explain the short periods of busy trading (mostly selling over the last 18 months) amidst long stretches with practically no activity?

As a LTI, I would welcome a detailed statement of the company’s aspirations, including future revenue projections based on our selling strategies. Additionally, a summative statement on the outcome of the Ph1 stage of the GaM trial, as soon as it is available.

Only then will I have some idea of our true value, and the time scale needed to achieve significant growth - initially back to the c. 5p level of 18 months ago. Perhaps we will be told more at the forthcoming AGM?

GLA.

Semantic.

This preoccupation, as you call it, only exists due to the significant effect that TEB's actions has had on IQ-AI's share price, and consequently on my investment. The company's share price was on an upward trajectory at the end of 2023. Look where it is now! This is in spite of the positive statements, on two fronts, that have regularly emerged from IB, and in RNSs from IQ-AI, since then.

I agree that there are far more important matters to discuss, but the scars from the self-interest shown by TEB and his family remain. This is evident in the share price that resulted from their actions.

When IBAI, as we shall soon be, shows signs of moving forward, and my investment is in profit, I will be fully focused on our future prospects. Meanwhile the disappointment from the result of our CEO's actions remains.

Having read last Friday’s statement carefully several times, my view is that it is a fair and comprehensive statement of where we are, and where IBAI is heading this year. I already knew about most of this, but it was good to have a summative statement.

I agree that some of our CEO’s past actions have proven to be detrimental to the share price . Hopefully that is behind him, and he will focus his attention on increasing the sales of IB’s technology, and on the post Ph1 planning of the GaM trial.

Having been previously invested in a disastrous biopharmaceutical company in which the CEO deliberately (or otherwise) lied to investors for 3 years, while achieving nothing, I feel that I am better informed, and therefore more confident about my prospects here.

That being said we need to demonstrate substantial revenue growth from our suite of innovative diagnostic technology to bring about a short term recovery in the MCap/share price commensurate with the quality of IB’s achievements on two broad fronts.

I sincerely hope that our CEO is sincere in his recent comments. I have already suffered from being turned over due to believing the lies of one shark. I can well do without the same happening again.

GLA.

Thank you Kane. That X message, together with a long string of other IB posts sums up the retail investors’ dilemma. We seem to be invested in a very credible and creative micro company with great potential. Why isn’t this reflected in the share price? Yesterday, we saw over 1% of the company’s shares sold in a day for a pittance. The share price correspondingly fell by >9% to the point that it is close to the all-time low value, which was also reached recently.

Why did yesterday’s sell off happen? The seller(s) was/were evidently not seriously invested in IQ-AI. The recent GaM trial update, and Kane’s summary X message suggest that IB has considerable potential.

Why then dump more than 1% of the company for a miserly sum, and further reduce the share price? This is not the action of a someone with a real interest in IQ-AI. It remains a worrying time for long term retail investors.

Fair point Tyke. Thank you.

For sure though, what we have seen, since I have been invested, is not an acceptable template for running a company with noble aspirations. Let us hope that the undoubted quality in IB’s work and eventually bears fruit for all concerned.

GLA,

Another DELIBERATE unexpected selloff of 2,209,606 shares to date today, in a short spell, taking the share price back into all-time low territory. An apalling year to date for IQ-AI, following a terrible 2024. None of this tallies with the last RNS,for which we might have reasonably expected a sustained rise in the share price?

The recent placement could only have been to cover IQ-AI execs' wages and expenses. Our best information suggests that IB is self-sustaining?

When are the CEO and his team going to bring about some measures to effect a positive impact? Clearly, his family's selloff of their entire shareholding destroyed the share price, and, with it, market confidence in this company! IB's continuous positive messages about the GaM trial, and the quality of their diagnostics, are alone insufficient to impress prospective investors!

Thank you howdlep. I fully concur.

The potential of this investment has been in plain sight for years. I have remained invested, but the expected growth hasn’t happened? I am at a loss to explain why not?

I am also grateful to max for continuously updating this forum on the latest IB news. Someone on here compared once our situation with Amazon, which remained under investors’ radar for a long time before its potential was finally noticed. Are there parallels to be drawn here?

What will it take for IB’s excellent work to attract investment from a large entity? The current MCap of around £2m must be considerably below true valuation, when one considers the value of the IP attached to IB’s products alone? There is also the outcome of the GaM Ph1 trial, and its consequences to consider.

Surely TB’s market activity cannot be entirely to blame for our current position, although it hasn’t helped the investment case. All investors can but hope that IQ-AI will henceforth be fully focused in raising awareness of the enormous potential that IB offers, and finally attract some significant attention and support?

Yesterday’s small gain through several trades at a consistent level has been cancelled by a single large-ish trade this morning.

We are in need of significant news to add stability to the share price, and promote more buys. The month of May is rapidly approaching. Does the “Sell in May, and go away” rule apply here? Unfortunately the recent placement suggests to me that significant news is unlikely to happen for the time being?

But, who am I to know anything? My lack of understanding was exposed by my 4+ years of holding shares in a rogue company, with a less than competent CEO at the helm!

Yes, SNG is the company I was referring to. The SNG execs and BOD paid themselves high salaries, from the residue of the funds raised for a catastrophic trial, - for three long years. In that time, they achieved nothing whatsoever!

To our benefit here, there is a far higher level of competence, and more transparency from IB, than investors were ever shown by SNG. I am hopeful of an eventual beneficial outcome for everyone involved here, retail investors in particular.

Good morning Laura.

Thank you. I do not have access to that information.

The rise to a significant share price (600-700% to return to Dec 2023 levels) will only be possible if we receive a concrete update from the company. By this I mean news of a substantial increase in revenue from product sales, or a promising outcome from the Phase 1 GaM trial. The latter could result in one of several outcomes, which might benefit the company.

Any progress will depend on the implementation of beneficial measures for the good of the company from the CEO and Board. Unfortunately, CEO’s actions in particular don’t always benefited retail investors.

My recent experience concerning a rogue CEO from another company - a “Judge me at the EGM” comment, which led to the wipeout of all retail investors, has led to a high degree of mistrust in CEOs in particular. Hopefully, we won’t see anything similar happening here?

The London Stock Exchange is quoting 0.77/0.83 at a share price of 0.8p. My broker values my stock at the current share price. They usually quote a significantly lower price. Does this indicate buying pressure ahead? Let’s hope so, as we have only experienced share price decline to date this year. Market confidence has been low since the CEO and his family offloaded their shareholding. A MCap of £10m, as was the case at the time, would surely represent “fair” value at the moment, when one considers what the company has to offer?

I am surprised that large entities are not looking at adding our imaging technology incorporating AI to their portfolio? I should add that many including myself had similar thoughts about a small biopharmaceutical company, which recently kicked their retail investors in the backside. Hopefully, we won’t experience a similar outcome here, but one never knows?

I am hoping for a return to a higher share price in the near future. The current MCap makes no sense whatsoever. The recent information concerning IB’s high definition tumour imaging underpinned by AI driven diagnostics, and the progress made in the GaM trial, suggests that the company is undervalued.

Unfortunately, this is contradicted by the recent placement, which literally halved the share price from an already low level of 1.4p. The CEO and Board would not be raising funds, presumably to pay their salaries and other company expenses, if there was imminent news to the company’s advantage on the horizon?

Currently, the sell price for 50K shares is 0.751p. Is this the bottom? Were they recent sells partly to do with the fact that we are nearing the end of the financial year? Were recent purchasers of IQAI stock disposing of it due to lack of progress? Perhaps the issuing of 25m new shares for a tiny amount prompted the sells?

I can but speculate because I don’t know. Like others here, I can but hope that the investments of long term retail investors are part of this company’s future plans. Having seen the shabby treatment recently dispensed on LTIs by another tiny company recently, I remain wary! GLA.

“revenue” not “revenge”.

Today’s first trade suggests that the share dumping is continuing and that a lower share price beckons?

An excellent summary howdlep, as always. I am aware from your previous posts that your research is detailed and thorough.

I agree that TB’s activities are currently determining the course of this company. It would appear that he is focused on benefiting himself, and his associates, apparently to the detriment of retail investors? It is probably time for him to step down.

MS would be an ideal replacement, as the future of the company rests on what IB is able to achieve. I have little information about IB’s revenue and projected future growth. Currently it rests on the sales of its diagnostic products; hopefully they are going down a licensing route, to generate continued revenge for future upgrades to their software?

I appreciate that the GaM trial is another iron in the fire. As is the case with clinical trials, it is taking a long time to complete the Ph1 stage. It seems likely that it will subsequently progress to a Ph2 trial. Hopefully, TB will not be involved at the Ph2 funding stage. Past precedent suggests that he might work it to his own advantage, with a massive share dilution to the detriment of current retail investors?

Unfortunately, I recently lost a lot of capital in a biopharmaceutical company, which was totally mismanaged by an incompetent CEO, and inexperienced CSO. The executives of IQAI are nowhere near that category, but I am more wary than before. As an investor, it is my view that it is high time that we were given some evidence of progress in IB’s promising initiatives. As said previously, the newsletters and X messages are indicative of progress, but add no value. Hopefully, some indication of future revenue growth will be forthcoming? GLA